1174705-36-2

Upstream product

• 855776-96-4 7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazole-5-carboxaldehyde 
• 855777-75-2 C₂₃H₃₅N₃O₅Si 
• 855777-76-3 (+/-)-methyl 2-(tert-butoxycarbonylamino)-3-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}methyl]-2H-indazol-5-yl)propanoate 
• 855777-77-4 (+/-)-tert-butyl 1-hydroxy-3-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}methyl]-2H-indazol-5-yl)propan-2-ylcarbamate 
• 855778-55-1 (+/-)-tert-butyl 1-(4-methyl-1H-imidazol-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate 
• 855778-56-2 (+/-)-tert-butyl 1-(1-(3-fluorobenzyl)-4-methyl-1H-imidazol-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate 

Relevant academic research and scientific papers

Preparation of imidazoles as potent calcitonin gene-related peptide (CGRP) antagonists

Several new potent CGRP receptor antagonists have been prepared in which the amide bond of lead compound 1 has been replaced by bioisosteric imidazole moieties. Substitution at N-1 of the imidazole was optimized to afford compounds with comparable potency